Julie L Lane

US Patent:

20020018774, Feb 14, 2002

Filed:

Dec 17, 1998

Appl. No.:

09/213678

Inventors:

SIMON GREEN - PLEASANTON CA, US
GARY DALLMANN - MENLO PARK CA, US
MAGDELEINE HUNG - HAYWARD CA, US
JULIE LANE - OAKLAND CA, US
CHARLES M. MOEHLE - CASTRO VALLEY CA, US

International Classification:

G01N033/53
C12N005/00
C12N015/70
C12P021/06
A61K039/395
C12N015/74
C12N015/63
C12N015/09
G01N033/569
C07H021/04
C12P021/04
C12N015/00
C12N005/02

US Classification:

424/130100, 536/023500, 435/320100, 435/325000, 435/071200, 435/069100, 435/007100, 435/975000

Abstract:

The present invention relates to enzymes involved in capping of fungal mRNAs, and molecules that inhibit such enzymes. In particular, the invention relates to the novel capping enzyme genes ABD1 and CET1 and their encoded protein products, as well as derivatives and analogs thereof. The invention also relates to methods of using of fungal capping enzymes to screen for fungal inhibitors.

US Patent:

53765460, Dec 27, 1994

Filed:

Jun 19, 1992

Appl. No.:

7/901707

Inventors:

Susan L. Bernhard - Menlo Park CA
Marc D. Better - Los Angeles CA
Steve F. Carroll - Walnut Creek CA
Julie A. Lane - Castro Valley CA

Assignee:

Xoma Corporation - Berkeley CA

International Classification:

C12N 922
C07K 1300

US Classification:

435199

Abstract:

The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins and analogs thereof having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. Preferred analogs according to the present invention are analogs of Type I ribosome-inactivating proteins (1) having a cysteine available for intermolecular disulfide bonding located at an amino acid position corresponding to a position not naturally available for intermolecular disulfide bonding in the Type I ribosome-inactivating protein and corresponding to a position on the surface of ricin A-chain in its natural conformation and (2) retaining ribosome-inactivating activity of the Type I ribosome-inactivating protein. The RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents and, more specifically, as components of immunotoxins. Cytotoxic agents according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.

US Patent:

54162025, May 16, 1995

Filed:

Dec 9, 1992

Appl. No.:

7/988430

Inventors:

Susan L. Bernhard - Menlo Park CA
Marc D. Better - Los Angeles CA
Steve F. Carroll - Walnut Creek CA
Julie A. Lane - Castro Valley CA

Assignee:

XOMA Corporation - Berkeley CA

International Classification:

C07H 2102
C12N 1570
C12N 121

US Classification:

536 232

Abstract:

The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) such as gelonin and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.

US Patent:

49487299, Aug 14, 1990

Filed:

Mar 17, 1988

Appl. No.:

7/171132

Inventors:

Michael Piatak - Walnut Creek CA
Walter J. Laird - Pinole CA
Julie A. Lane - Oakland CA

Assignee:

Cetus Corporation - Emeryville CA

International Classification:

C12P 2100
C12N 1500
C12N 120
C07H 2104

US Classification:

436 68

Abstract:

A system for expression of coding sequences for desired heterologous proteins in procaryotic hosts whereby the protein is produced intracellularly in soluble, biologically active form, is disclosed. The expression is obtained by ligation of the coding sequence downstream of, and proximally to, but out of reading frame with, the terminated leader encoding sequence for a secreted bacterial protein, such as alkaline phosphatase. The resultant proteins are influenced by the leader sequence codons to effect the desired three-dimensional conformation, but not to effect secretion.